COG5-Congenital Disorder of Glycosylation (COG5-CDG)

COG5-congenital disorder of glycosylation (COG5-CDG) is a very rare genetic disease. It happens when the COG5 gene does not work properly. This gene helps a cell add small sugar chains to proteins and fats. This sugar-adding process is called glycosylation and happens in a cell part called the Golgi apparatus. When glycosylation is faulty, many organs in the body do not work well, especially the brain, muscles, liver, and sometimes the heart.

COG5-congenital disorder of glycosylation (COG5-CDG) is an ultra-rare genetic, metabolic and neurological disease. It happens when both copies of the COG5 gene are changed (mutated), so the Golgi apparatus in cells cannot attach sugar chains (glycans) to proteins in a normal way. This faulty glycosylation affects many organs, especially the brain, liver, muscles, eyes and growth. Children usually show low muscle tone (hypotonia), delayed motor and speech development, seizures, feeding problems, short stature, small head size, and distinctive facial features. COG5-CDG is inherited in an autosomal recessive pattern, and at present there is no cure; management is focused on treating symptoms, protecting organs and improving quality of life through multidisciplinary care.

COG5-CDG is inherited in an autosomal recessive way. This means a child gets one changed (mutated) COG5 gene from each parent. The parents are usually healthy carriers. The disease often starts in infancy with weak muscles, slow development, and feeding problems. Because glycosylation is needed in almost every cell, doctors call this a “multi-system” disorder.

Other names

Doctors and books may use different names for the same disorder. These are common other names:

1. COG5-congenital disorder of glycosylation (COG5-CDG) – the current gene-based name.

2. Congenital disorder of glycosylation type IIi (CDG-IIi) – the older “type II” name used before the gene-based system.

3. Congenital disorder of glycosylation type 2I (CDG-2I) – another form of the older numeric naming for the same condition.

4. Carbohydrate-deficient glycoprotein syndrome type III – a historical name, less used now, that also points to abnormal sugar chains on proteins.

5. COG5-CDG, formerly CDG-IIi – often written this way in research papers to show both the old and new names together.

Types

There are no official “subtypes” based on the COG5 gene itself. But doctors sometimes group patients in simple ways based on how sick they are:

• Severe form – very weak muscles, severe developmental delay, trouble feeding, possible early serious complications.

• Moderate form – clear developmental problems and organ involvement, but children may learn some skills and live longer.

• Mild form – milder delay or learning problems, sometimes diagnosed later in childhood if symptoms are less obvious.

These “types” describe clinical severity only. They are not different genetic diseases.

Causes

Below are 20 simple “causes and mechanisms” that explain why and how COG5-CDG happens.

1. Pathogenic variants in the COG5 gene
   The main cause is a harmful change (mutation) in the COG5 gene. This mutation stops the gene from making a normal COG5 protein. Without a normal protein, the Golgi complex cannot move and process proteins correctly.

2. Autosomal recessive inheritance
   COG5-CDG follows an autosomal recessive pattern. A child must receive one mutated copy of COG5 from each parent. Parents usually have one good copy and one bad copy, so they are healthy carriers.

3. Homozygous mutations
   Some patients have the same mutation on both copies of the COG5 gene (homozygous). This often happens in families where parents are related (consanguineous). Homozygous mutations can completely block normal COG5 function.

4. Compound heterozygous mutations
   Other patients have two different mutations, one on each copy of the gene (compound heterozygous). Together, these different changes still prevent the COG5 protein from working as it should.

5. Missense mutations
   Missense mutations change one amino acid in the COG5 protein. Even a single change can make the protein fold wrongly or fail to join the larger COG complex, so glycosylation becomes faulty.

6. Nonsense and frameshift mutations
   Nonsense or frameshift mutations can cut the protein short or stop it from being made at all. These “loss-of-function” changes are strong causes of disease because very little working COG5 protein is left.

7. Defective COG complex (lobe B) assembly
   COG5 normally sits in the COG complex with the COG6, COG7, and COG8 proteins (called lobe B). If COG5 is abnormal, the whole lobe B structure becomes unstable, and vesicle traffic in the Golgi breaks down.

8. Abnormal Golgi structure and trafficking
   The COG complex helps keep the Golgi apparatus in the right shape and helps tiny transport bubbles (vesicles) move. When COG5 is defective, Golgi structure is distorted, and traffic inside the cell slows or stops.

9. Faulty N-linked glycosylation
   COG5-CDG belongs to the “type II” CDG group, where trimming and processing of sugar chains on proteins in the Golgi is faulty. This leads to abnormal N-linked glycosylation patterns on many serum and cell proteins.

10. Abnormal glycosylation of many body proteins
    Because COG5 helps handle many glycoproteins, mutations cause widespread under- or mis-glycosylation. This affects hormone receptors, clotting factors, transport proteins, and structural proteins all over the body.

11. Impaired brain development
    The developing brain needs many correctly glycosylated proteins for cell signaling and migration. Faulty glycosylation from COG5 mutations leads to learning problems, movement problems, and sometimes brain structure changes on MRI.

12. Muscle and nerve dysfunction
    Muscles and nerves also rely on glycoproteins in cell membranes. Abnormal glycosylation leads to poor muscle tone (hypotonia), weakness, and sometimes peripheral neuropathy or coordination problems.

13. Liver dysfunction from mis-glycosylated proteins
    The liver makes many glycoproteins, such as clotting factors and transport proteins. When glycosylation is abnormal, these proteins are not stable or not secreted correctly, leading to liver enzyme changes and other liver problems.

14. Coagulation factor defects
    Some clotting factors need proper glycosylation. In CDG, clotting tests may be abnormal, and patients may bruise or bleed more easily because these proteins do not work well.

15. Consanguinity (related parents) as a risk factor
    In populations where marriage between relatives is more common, there is a higher chance that both parents carry the same rare COG5 mutation. This increases the chance of a child being affected.

16. Family history of CDG or unexplained infant problems
    A history of siblings with unexplained developmental delay, early death, or a known CDG can point to a shared COG5 mutation in the family. This background is an important “cause clue” for doctors.

17. De novo (new) mutations
    In some genetic diseases, a mutation can appear for the first time in a child (de novo). While COG5-CDG is usually recessive with inherited changes, de novo variants may sometimes contribute to the pattern in complex families.

18. Interaction with other COG subunit defects
    Research shows that problems in one COG subunit can overlap in symptoms with defects in another, such as COG7. This suggests that disturbed interactions between subunits at the protein level help cause the clinical picture.

19. Extremely rare frequency (founder effects)
    Because COG5-CDG is extremely rare worldwide, some cases may be due to “founder” mutations in small populations, where one old mutation spreads in a community over generations.

20. No lifestyle or environmental cause
    There is no evidence that diet, infection, pregnancy behavior, or other lifestyle factors cause COG5-CDG. The disease is caused by gene changes present from conception; environment may affect severity but is not the root cause.

Symptoms

1. Developmental delay
   Many children with COG5-CDG learn to sit, stand, walk, and talk later than usual. This happens because their brain cells and nerve connections do not work normally due to faulty glycosylation.

2. Intellectual disability or learning problems
   Some children have difficulty with thinking, understanding, and school learning. The level can range from mild learning difficulty to moderate intellectual disability.

3. Low muscle tone (hypotonia)
   Babies may feel “floppy” when held. Their muscles resist movement less than normal. This makes it hard to hold up the head, sit, or walk at the usual age.

4. Muscle weakness and fatigue
   Children may tire quickly, have trouble climbing stairs, or have poor endurance. Weak muscles also affect posture and balance.

5. Poor coordination and ataxia
   Some patients have shaky or clumsy movements, with difficulty controlling the arms and legs smoothly. This is called ataxia and is common in several CDG types.

6. Seizures
   Seizures (fits) can occur in some children. They may be brief staring spells, jerking of the limbs, or other seizure types. These events reflect abnormal electrical activity in the brain.

7. Feeding difficulties in infancy
   Babies may have trouble sucking, swallowing, or coordinating breathing while feeding. They may vomit often or fail to gain enough weight, which doctors call “failure to thrive.”

8. Growth problems and small body size
   Children may grow more slowly in height and weight than their peers. This may be due to poor nutrition from feeding problems, hormonal effects, and chronic illness together.

9. Liver problems
   Some patients have raised liver enzymes in blood tests, enlarged liver, or other signs of liver dysfunction, because many liver proteins are mis-glycosylated and do not work well.

10. Abnormal blood clotting (bleeding or bruising)
    Because clotting factors made by the liver are not glycosylated correctly, the blood may clot too slowly. Children may bruise easily or bleed longer after minor injuries or surgery.

11. Characteristic facial features
    Some patients have subtle facial differences, such as a high forehead or unusual fat pads, similar to other CDG types. These features are not always present but can help doctors suspect the diagnosis.

12. Eye and vision problems
    Vision can be affected by eye movement problems, optic nerve issues, or refractive errors. Abnormal glycosylation can disturb the development of eye structures and visual pathways.

13. Skeletal or joint abnormalities
    Some CDG patients have skeletal changes or loose joints due to abnormal connective tissue glycoproteins. In COG5-CDG, joint laxity or spine and limb changes may appear in some individuals.

14. Behavioral or emotional difficulties
    Children may show hyperactivity, irritability, or autistic-like features. These behaviors come from the way the brain is affected and the challenges of living with a chronic condition.

15. Serious multi-organ involvement in severe cases
    In more severe forms, several organs (brain, liver, heart, gut) are affected at the same time. This can lead to repeated hospital stays and may limit life expectancy in some patients.

Diagnostic tests

Doctors use a mix of physical examination, bedside (manual) tests, laboratory and pathological tests, electrodiagnostic tests, and imaging to diagnose COG5-CDG. First they suspect a congenital disorder of glycosylation from the pattern of symptoms and lab results. Then they confirm the exact gene problem with genetic testing.

Physical examination tests

1. General physical and growth exam
   The doctor checks weight, height, head size, and body proportions. They look for poor growth, low muscle bulk, unusual fat pads, inverted nipples, or other signs seen in CDG. This broad exam gives early clues that a multi-system genetic disorder may be present.

2. Neurological examination
   The neurologist tests muscle tone, strength, reflexes, posture, and eye movements. They look for hypotonia, weakness, ataxia, or abnormal reflexes. These findings support a brain and nerve problem consistent with COG5-CDG.

3. Eye and vision examination
   An eye doctor (ophthalmologist) checks eye movements, alignment, and the back of the eye (the retina and optic nerve). Problems like strabismus (crossed eyes), nystagmus, or optic nerve changes can be seen in CDG.

4. Abdominal examination for liver and spleen
   The doctor gently feels the abdomen to check if the liver or spleen are enlarged. An enlarged liver (hepatomegaly) suggests liver involvement, which is common in glycosylation disorders.

Manual tests

5. Developmental milestone screening
   Simple bedside tools and questions are used to see when the child smiled, sat, stood, walked, and spoke. Delays in several areas of development raise suspicion of a genetic metabolic disorder such as COG5-CDG.

6. Manual testing of muscle tone and strength
   The doctor moves the child’s arms and legs and asks older children to push or pull against resistance. They judge how floppy or stiff the muscles are and how strong they feel, helping to document hypotonia and weakness.

7. Coordination and balance tests
   Older children may be asked to touch their nose, walk in a straight line, or stand on one leg. Difficulty with these tasks suggests ataxia or poor coordination, which fits with many CDG types.

Lab and pathological tests

8. Serum transferrin glycoform analysis
   A key screening test for CDG examines the sugar pattern on a blood protein called transferrin. In CDG type II, including COG5-CDG, the pattern is abnormal. This test is done by isoelectric focusing or mass spectrometry.

9. Serum N-glycan profiling
   More detailed mass spectrometry can study many N-linked sugar chains in the blood. A typical “type II” glycan pattern supports a diagnosis of a processing defect in the Golgi, as seen in COG5-CDG.

10. Liver function tests
    Blood tests such as ALT, AST, GGT, and bilirubin help check liver health. Abnormal values support the idea that glycosylation defects are harming liver cells and liver-made proteins.

11. Coagulation studies (PT, aPTT)
    Tests that measure how long blood takes to clot can show prolonged clotting times in CDG. This reflects mis-glycosylated clotting factors made by the liver.

12. Serum albumin and protein studies
    Levels of albumin and other serum proteins may be low or abnormal. Special tests can show under-glycosylated forms of these proteins, which is typical in many glycosylation disorders.

13. Basic metabolic panel and lactate
    Routine tests for electrolytes, glucose, and lactate help rule out other metabolic diseases and show any extra stress in the body due to chronic illness.

14. Targeted COG5 gene sequencing
    Once CDG is suspected, DNA sequencing of the COG5 gene can look for harmful variants. Finding two disease-causing mutations confirms the diagnosis of COG5-CDG.

15. Whole-exome or whole-genome sequencing
    In complex cases, broad sequencing of many genes (exome or genome) can find COG5 mutations and also check for other rare genetic conditions. This is useful when the clinical picture is unclear.

Electrodiagnostic tests

16. Electroencephalogram (EEG)
    An EEG records the electrical activity of the brain using small scalp electrodes. It helps detect seizure activity and abnormal brain rhythms, which are common in children with CDG-related epilepsy.

17. Nerve conduction studies and EMG
    These tests measure how fast and how well nerves send signals to muscles, and how muscles respond. They can show peripheral neuropathy or myopathy, which may appear in some CDG patients.

Imaging tests

18. Brain MRI
    Magnetic resonance imaging (MRI) uses strong magnets to create pictures of the brain. In some CDG patients, MRI shows cerebellar hypoplasia (small cerebellum) or other changes that match the child’s movement and coordination problems.

19. Abdominal ultrasound
    Ultrasound uses sound waves to look at the liver, spleen, and other organs. It can show an enlarged liver or other structural changes related to glycosylation problems.

20. Echocardiography (heart ultrasound)
    Some CDG types can involve the heart. An echocardiogram checks heart structure and pumping function. It helps find valve problems or cardiomyopathy that might need extra care.

Non-pharmacological treatments (therapies and others)

1. Multidisciplinary care and care coordination
People with COG5-CDG usually need a team including metabolic specialists, neurologists, hepatologists, cardiologists, physiotherapists, dietitians, speech therapists, psychologists and social workers. Regular team meetings and shared care plans help track growth, development, seizures, liver function and other complications in a structured way. This coordinated approach allows faster responses to new problems and avoids conflicting advice, which is very important in a complex multi-system disease like CDG.

2. Physiotherapy for hypotonia and motor delay
Physiotherapy uses guided exercises, stretching and play-based activities to improve muscle tone, posture and balance. In COG5-CDG, many children are “floppy,” late to sit, stand or walk, or may never walk independently. Regular physiotherapy can help prevent joint contractures, support better head and trunk control, reduce falls and improve comfort in wheelchairs or standing frames, even if full independence is not achievable.

3. Occupational therapy for daily living skills
Occupational therapy focuses on hand use, self-care skills and environmental adaptations. Therapists can recommend special seating, adapted cutlery, communication switches, and positioning aids to make feeding, dressing, writing and playing easier. For a child with COG5-CDG, the goal is not perfection but maximum independence and safety in daily activities, which can also reduce caregiver strain and improve self-confidence.

4. Speech and language therapy
Many individuals with COG5-CDG have delayed or absent speech, low oral muscle tone and swallowing difficulties. Speech therapists can work on early communication through gestures, pictures and communication devices, as well as safe chewing and swallowing techniques. Therapy aims to prevent choking, improve nutrition, and give the child a way to express needs and emotions, which can reduce frustration and behaviour problems.

5. Early intervention and special education services
Early intervention programs provide structured learning and therapies during the first years of life, when the brain is most plastic. For COG5-CDG, they usually combine play-based motor, cognitive and social stimulation. Later, special education classes or inclusive schooling with individual support can target literacy, numeracy and life skills, adapted to the child’s cognitive level and attention span.

6. Orthotic devices and mobility aids
Braces, ankle–foot orthoses, standing frames, walkers and wheelchairs help keep joints aligned and support safe mobility. In COG5-CDG, ataxia, weakness and poor balance make falls and deformities more likely. Proper orthotic support reduces energy use during walking, prevents foot and knee deformities, and allows the child to participate more in school and family activities.

7. Nutritional counselling and high-calorie feeding plans
Feeding difficulties and failure to thrive are common in CDG. A dietitian can design high-calorie, nutrient-dense meal plans, sometimes using thickened fluids or special formulas. The aim is to support growth, preserve muscle mass and protect immune and liver function, while avoiding aspiration. The plan is adjusted frequently as the child’s weight, activity level and medical issues change.

8. Gastrostomy (PEG) feeding support and training
When oral intake is unsafe or insufficient, a percutaneous endoscopic gastrostomy (PEG) tube may be placed, but everyday care is non-pharmacological. Families learn how to keep the stoma clean, manage tube feeds, and watch for infection or leakage. For COG5-CDG, PEG feeding can reduce mealtime stress, improve weight gain and allow reliable medication administration, especially during illnesses.

9. Swallowing therapy and positioning strategies
Speech and occupational therapists can teach chin-tuck, slow pacing, appropriate food textures and upright sitting to reduce choking and aspiration. For a child with COG5-CDG, whose muscle tone and coordination are poor, these simple strategies may greatly lower the risk of pneumonia and hospitalisation, and they often make feeding times calmer and more enjoyable.

10. Non-drug seizure safety measures
Even when medicines control seizures, families are taught basic safety: supervising baths, avoiding heights, using padded furniture and helmets when needed, and recovering position after a seizure. For COG5-CDG, clear emergency plans at home and school explain what to do during a seizure and when to call emergency services, which can prevent injury and anxiety.

11. Vision rehabilitation and low-vision aids
Some people with COG5-CDG have retinal degeneration or other visual problems. Low-vision specialists can provide contrast-rich materials, magnifiers, glasses, orientation training and classroom adaptations. The goal is to maximise remaining vision, support safe mobility, and adapt learning tasks, helping the child stay engaged in school and play despite visual impairment.

12. Hearing support and audiology care
Hearing loss or auditory processing problems may also occur. Regular audiology checks, hearing aids, and classroom FM systems help children with COG5-CDG detect speech and environmental sounds. Better hearing can markedly improve language learning, social interaction and safety in daily life, especially in busy or noisy settings like school or public transport.

13. Behavioural and developmental therapy
Behaviour specialists and developmental psychologists can help manage self-stimulation, anxiety, attention problems or challenging behaviours linked to frustration or communication difficulties. They use positive reinforcement, routines and visual schedules. For families of a child with COG5-CDG, this support reduces conflicts, improves sleep and feeding routines, and helps everyone feel more in control.

14. Psychological and social support for caregivers
Parents and siblings often experience stress, grief and financial pressure. Access to counselling, parent support groups, respite care and community resources is a key non-pharmacological “therapy.” Emotional support helps families cope with uncertainty, complex care routines and repeated hospital visits, and it reduces the risk of depression and burnout in caregivers.

15. Respiratory physiotherapy and airway clearance
Because hypotonia and poor coordination can impair coughing, respiratory physiotherapy (postural drainage, assisted coughing, breathing exercises) helps clear mucus and prevent infections. For COG5-CDG, this is especially useful after viral illnesses or surgery, when immobility and sedation further reduce lung function. Better airway clearance lowers the risk of pneumonia and hospital stays.

16. Orthopaedic rehabilitation and contracture prevention
Regular stretching, splinting and positioning prevent joint contractures and scoliosis caused by long-term muscle weakness, abnormal tone and limited mobility. In COG5-CDG, these measures are often started early, before fixed deformities appear. Good posture and spinal alignment improve breathing, feeding, comfort and sitting tolerance in wheelchairs or special chairs.

17. Liver-protective lifestyle advice
For patients with liver involvement, lifestyle measures such as avoiding alcohol in adolescence/adulthood, maintaining healthy weight, staying vaccinated against hepatitis viruses and avoiding unnecessary hepatotoxic drugs can protect liver function. Although COG5-CDG liver disease is genetically driven, reducing extra liver stress can slow progression and lower the risk of cirrhosis-related complications.

18. Infection-control practices at home and school
Hand hygiene, up-to-date vaccinations, avoiding sick contacts, and rapid treatment of minor infections are very important because children with CDG can be medically fragile. Clear sick-day plans, early hydration and monitoring can prevent small infections from turning into serious illnesses or hospital admissions in COG5-CDG.

19. Genetic counselling for families
Genetic counselling explains the autosomal recessive inheritance pattern, recurrence risks for future pregnancies, and options such as carrier testing, prenatal diagnosis and preimplantation genetic testing. For families affected by COG5-CDG, this information helps with informed reproductive decisions and may bring emotional relief by clarifying why the condition occurred.

20. Palliative care and long-term planning
Palliative care for COG5-CDG does not mean “giving up”; it focuses on comfort, symptom control, and aligning treatments with the family’s goals and values. Teams can help with feeding decisions, seizure control, sleep, pain management and end-of-life planning if needed, providing continuous support across the disease course.

---

Drug treatments

Important: There is currently no specific FDA-approved drug that cures or directly corrects COG5-CDG itself. All medicines are used to treat associated problems like seizures, spasticity, reflux or infections. Exact choice and dose must always be decided by specialists.

1. Levetiracetam (Keppra)
Levetiracetam is a broad-spectrum antiepileptic drug that helps control focal and generalised seizures by modulating synaptic vesicle protein SV2A and reducing abnormal neuronal firing. It is usually given twice daily, with doses carefully adjusted to age, kidney function and seizure control. Common side effects include drowsiness, irritability and mood changes. In COG5-CDG, it is often chosen because it has few drug interactions and can be used in combination therapy.

2. Diazepam (Valium, injection or rectal/intranasal products)
Diazepam is a benzodiazepine that enhances GABA, the main inhibitory neurotransmitter in the brain, producing anticonvulsant, anxiolytic and muscle-relaxant effects. It is used as a rescue medicine for prolonged seizures or status epilepticus, usually given as a short course and not daily. Side effects include sleepiness, breathing suppression and dependence with long-term use, so careful medical supervision is essential.

3. Divalproex/valproic acid (Depakote)
Valproate increases GABA levels and affects sodium and calcium channels, making it effective for many seizure types. It is usually taken two or three times daily or as an extended-release tablet once daily. Important risks include liver toxicity, pancreatitis, weight gain, tremor and serious birth defects in pregnancy, so it must be used with strict monitoring and is often avoided in very young children and females of child-bearing potential when alternatives exist.

4. Clobazam
Clobazam is a benzodiazepine specifically used for epilepsy, often added when seizures remain frequent. It boosts GABA signalling, calming overactive brain circuits. It is given once or twice daily, with slow dose titration to reduce drowsiness or behaviour changes. Long-term use can cause tolerance and dependence, so clinicians regularly review its need, especially in children with CDG who may be sensitive to sedation.

5. Topiramate
Topiramate is a broad-spectrum antiepileptic medication that modulates sodium channels, GABA and glutamate receptors and has weak carbonic anhydrase-inhibiting properties. It is started at low doses and increased slowly, usually twice daily. Side effects include weight loss, tingling sensations, kidney stones and slowed thinking, so children are monitored closely for appetite and cognitive effects, especially in complex neurodevelopmental disorders like COG5-CDG.

6. Baclofen (oral)
Baclofen is a GABA-B receptor agonist used to reduce spasticity and painful muscle spasms. It is started in low divided oral doses and increased gradually, with a typical maximum adult dose around 80 mg daily, though children need lower weight-based doses. Side effects include drowsiness, dizziness and, with abrupt withdrawal, severe rebound spasticity or seizures, so dosing changes must be slow and supervised.

7. Omeprazole (Prilosec)
Omeprazole is a proton-pump inhibitor that blocks acid production in the stomach, used for reflux, heartburn and erosive oesophagitis. Many children with CDG have reflux and feeding difficulties, and acid suppression can reduce pain and vomiting. It is usually taken once daily before a meal. Long-term use may affect mineral absorption and infection risk, so doctors aim for the lowest effective dose and regular review.

8. Vitamin K supplementation
If COG5-CDG causes liver dysfunction and clotting problems, vitamin K can help correct some coagulopathy by supporting normal clotting factor activation. It may be given orally or by injection depending on severity. Excessive doses can rarely cause haemolysis in certain newborns, so monitoring of clotting tests (INR, PT) and liver enzymes is essential during treatment.

9. Ursodeoxycholic acid (UDCA)
UDCA is a bile acid that can improve bile flow and protect liver cells in cholestatic liver disease. In CDG patients with cholestasis or abnormal liver tests, UDCA may relieve itching, improve digestion of fats and potentially slow liver damage. Typical dosing is weight-based and divided over the day. Side effects are usually mild, such as diarrhoea, but regular liver monitoring is still required.

10. Antiemetic medicines (for nausea and vomiting)
Children with COG5-CDG may suffer recurrent vomiting from reflux, infections or seizures. Short-term use of antiemetic drugs, such as ondansetron, can control severe nausea and help maintain hydration and medication intake. Because some antiemetics can affect heart rhythm or cause constipation, clinicians choose carefully, limit duration, and monitor ECG and bowel habits when needed.

11. Laxatives and stool-softeners for constipation
Chronic constipation is common due to hypotonia, limited mobility and some seizure medicines. Osmotic laxatives or stool-softeners help keep stools soft and regular, reducing pain, faecal soiling and risk of bowel obstruction. Dosing is adjusted slowly to avoid diarrhoea or dehydration, and is combined with fluids, fibre and physical activity where possible.

12. Vitamin D and calcium supplements
Low mobility, poor nutrition and some antiepileptic drugs can weaken bones. Vitamin D and calcium supplements help maintain bone mineralisation and lower fracture risk. Doses are based on blood levels, age and dietary intake. Careful monitoring prevents toxicity, which can cause high calcium levels, kidney stones and nausea, especially when used with certain diuretics or high-dose vitamin preparations.

13. Multivitamin and trace-element preparations
Children with feeding difficulties may lack vitamins and minerals such as iron, zinc or B-group vitamins. Balanced multivitamin supplements support immune function, growth and wound healing. Doctors choose formulations appropriate for age and liver or kidney status to avoid accumulation of fat-soluble vitamins, and they monitor blood counts and micronutrient levels when possible.

14. Iron supplements (if iron-deficiency anaemia is present)
Poor intake, chronic disease and frequent blood tests can cause iron-deficiency anaemia. Oral or sometimes intravenous iron improves haemoglobin, energy and cognitive function. Doses are weight-based and given with monitoring of ferritin and haemoglobin. Side effects include stomach upset, constipation or dark stools, so adjustments and supportive measures are often needed.

15. Antibiotics for recurrent infections
Because COG5-CDG can affect immunity and feeding, recurrent respiratory or urinary infections are common. Appropriate antibiotics, selected based on local guidelines and cultures, are essential to prevent serious complications like sepsis or lung damage. They are used for clear bacterial infections, not viral illnesses, to reduce resistance and side effects such as diarrhoea and allergic reactions.

16. Anticoagulants or antiplatelet agents (in selected patients)
Some CDG types are linked to clotting abnormalities that can cause thrombosis or bleeding. In carefully selected cases, low-dose aspirin or anticoagulants may be given to reduce clot risk. This decision is complex and based on laboratory tests and clinical history, because these drugs themselves can cause dangerous bleeding if not monitored closely.

17. Growth hormone therapy (rare, selected cases)
If a child with COG5-CDG has proven growth hormone deficiency and no major contraindications, growth hormone injections may be considered to improve height and body composition. Therapy requires frequent monitoring of growth velocity, glucose levels and IGF-1, and it is not used simply for short stature without clear deficiency because of cost and potential side effects.

18. Proton-pump inhibitors or H2 blockers (other agents)
Besides omeprazole, other acid-suppressing medications may be used when reflux is severe or omeprazole is not tolerated. They reduce gastric acid, helping oesophagitis to heal and decreasing pain during feeding. Long-term therapy requires review because acid suppression can change gut microbiota and nutrient absorption, especially in medically complex children.

19. Analgesics for pain management
Simple analgesics like paracetamol (acetaminophen) or ibuprofen are commonly used for pain from procedures, infections or musculoskeletal problems. Doses are strictly weight-based, and maximum daily doses must not be exceeded to avoid liver or kidney injury. In children with liver disease, paracetamol dosing is especially cautious, and non-steroidal drugs may be restricted.

20. Sedatives for procedures or severe distress (short-term)
Short-acting sedative medicines may be needed for imaging, surgery or very distressing procedures. The choice of drug, dose and monitoring plan must take into account the child’s seizures, liver function and respiratory status. Continuous supervision in an appropriate setting is essential, because sedatives can suppress breathing, lower blood pressure and interact with existing medications.

---

Dietary molecular supplements

These supplements are supportive only and must be discussed with a metabolic specialist. Evidence for COG5-CDG specifically is limited; most information comes from broader CDG or metabolic disease experience.

1. L-carnitine
L-carnitine helps transport fatty acids into mitochondria for energy production. Some children with metabolic diseases have low carnitine levels, especially if on valproate. Supplementation, usually in divided oral doses, may improve fatigue and muscle weakness. Side effects include fishy body odour and mild stomach upset. Levels should be checked before and during therapy, as unnecessary high doses offer no extra benefit.

2. Coenzyme Q10 (ubiquinone)
CoQ10 is part of the mitochondrial electron transport chain and acts as an antioxidant. In some mitochondrial and metabolic disorders, CoQ10 supplements have been associated with modest improvements in energy and exercise tolerance. Typical doses are weight-based and given with food. Possible side effects are mild and include nausea or diarrhoea, but evidence in COG5-CDG is still limited and experimental.

3. Essential omega-3 fatty acids (EPA/DHA)
Omega-3 fatty acids from fish oil may support brain development, visual function and anti-inflammatory pathways. In neurodevelopmental disorders, they are sometimes used to help attention and behaviour, although evidence is mixed. Doses are usually calculated per kilogram of body weight, and fishy aftertaste or mild bleeding tendency at very high doses are potential side effects that clinicians consider.

4. Multivitamin with B-complex emphasis
B-group vitamins are co-factors for many metabolic reactions. In a child with limited dietary variety or malabsorption, a balanced multivitamin that includes B1, B2, B6, B12 and folate supports nerve function and blood cell production. Dosing follows age-specific recommendations, and very high doses are avoided to prevent toxicity, particularly for fat-soluble vitamins A, D, E and K.

5. Zinc supplements
Zinc is important for immune function, wound healing and taste. Poor intake or chronic diarrhoea can cause deficiency. Supplement doses are low and time-limited, based on blood levels and clinical signs such as poor growth, repeated infections or skin problems. Excessive zinc can interfere with copper absorption, so monitoring and medical guidance are essential.

6. Selenium supplements
Selenium works in antioxidant enzymes like glutathione peroxidase and helps protect cells from oxidative damage. In some metabolic and liver diseases, selenium deficiency is seen, and carefully monitored supplementation helps normalise levels. However, too much selenium can be toxic, causing hair and nail changes and neurological symptoms, so therapy must be guided by blood tests.

7. Medium-chain triglyceride (MCT) formulas
MCTs are fats that are more easily absorbed and used for energy, even when fat digestion is impaired. Special formulas containing MCTs may be useful in children with liver disease, malabsorption or failure to thrive. Doses are tailored to tolerance, as rapid increases can cause abdominal pain or diarrhoea. Their role in COG5-CDG is supportive and symptom-driven.

8. Protein or amino-acid supplements
If a child’s protein intake is limited by poor appetite or feeding problems, protein powders or amino-acid mixtures may help maintain muscle mass and immune function. They are added gradually to feeds to avoid intolerance. Kidney and liver function are checked, because excess protein can stress these organs in susceptible patients.

9. Prebiotic and probiotic preparations
Prebiotics and probiotics aim to support a healthy gut microbiome, which may influence digestion, immunity and possibly neurodevelopment. In children with frequent antibiotics and tube feeds, they may reduce diarrhoea or improve stool patterns. However, in very immunocompromised patients there is a theoretical infection risk, so specialists weigh benefits and risks before recommending them.

10. Experimental monosaccharide therapies (mannose, galactose, etc.)
In some other CDG types (for example MPI-CDG and PGM1-CDG), oral monosaccharide supplements like mannose or galactose have shown biochemical and clinical improvements by partially bypassing defective steps in glycosylation. For COG5-CDG, such therapies are experimental and not proven effective, so they should only be considered within research protocols or specialist centres.

---

Drugs for immunity support / regenerative or stem-cell–related approaches

There are no approved “stem cell drugs” specifically for COG5-CDG. The options below describe general concepts being explored in CDG and related disorders, mainly in research or highly selected situations.

1. Immunoglobulin replacement therapy (IVIG or SCIG)
If a patient with COG5-CDG has documented antibody deficiency and recurrent serious infections, immunoglobulin replacement may be considered to boost humoral immunity. It supplies pooled antibodies from healthy donors. Doses are weight-based and given regularly. Side effects can include headache, infusion reactions and, rarely, thrombosis or kidney problems, so therapy is usually reserved for clearly proven immunodeficiency.

2. Granulocyte-colony stimulating factor (G-CSF)
When neutropenia is present and infections are severe or frequent, G-CSF can stimulate bone marrow to produce more neutrophils, improving the body’s defence against bacteria. It is given as subcutaneous injections, with dosing adjusted to blood counts. Possible side effects include bone pain and, rarely, spleen enlargement, so monitoring is crucial. Use in COG5-CDG is individualised and specialist-led.

3. Erythropoiesis-stimulating agents (ESAs)
In chronic disease with significant anaemia not corrected by iron and nutritional support, ESAs can stimulate red blood cell production. This may reduce fatigue and transfusion needs. However, ESAs carry risks of high blood pressure and thrombosis and are generally reserved for specific indications; their role in COG5-CDG is limited and carefully considered.

4. Haematopoietic stem cell transplantation (HSCT) – experimental
HSCT replaces the patient’s bone marrow with donor stem cells. It has been used in a few glycosylation-related immunodeficiencies but is highly risky, with potential for graft-versus-host disease, infections and organ damage. For COG5-CDG, HSCT remains experimental, and there is no routine indication. Consideration would only occur in the context of severe immune or haematologic manifestations and expert multidisciplinary discussion.

5. Gene-therapy and gene-editing research
Future therapies may aim to correct COG5 mutations directly using viral gene transfer or gene-editing tools like CRISPR. At present, these strategies are still in pre-clinical or very early clinical stages for CDG and other metabolic disorders and are not available as standard treatment. Families should be informed about the experimental nature, possible benefits and serious unknown long-term risks.

6. Hepatocyte-targeted regenerative therapies (early research)
Some research focuses on delivering therapeutic molecules specifically to the liver, a major site of glycoprotein production, using nanoparticles or modified viral vectors. The aim is to improve glycosylation or protect liver cells. These approaches are still experimental and not specific to COG5-CDG yet, but they illustrate the regenerative direction of future treatment strategies.

Surgeries (procedures and why they are done)

1. Gastrostomy (PEG) tube placement
A PEG tube is placed through the abdominal wall into the stomach when oral feeding is unsafe or insufficient. In COG5-CDG, this surgery supports reliable nutrition, hydration and medication delivery, reduces aspiration risk, and lessens mealtime stress. It is usually a short procedure under sedation or general anaesthesia, followed by training for home care.

2. Orthopaedic tendon-lengthening surgeries
When contractures of the ankles, knees or hips become fixed and interfere with standing, walking or hygiene, surgeons may lengthen tendons or release tight soft tissues. For COG5-CDG patients with long-standing spasticity and weakness, these operations can improve positioning, relieve pain and make physiotherapy and daily care easier.

3. Scoliosis correction surgery
Severe scoliosis can develop due to hypotonia and prolonged sitting. Corrective spinal surgery aims to straighten and stabilise the spine, improving sitting balance, lung capacity and comfort. It is a major procedure with significant risks, so decisions weigh potential benefits against anaesthetic risks and recovery demands in a medically fragile child with COG5-CDG.

4. Liver transplantation (very selected cases)
If COG5-CDG leads to end-stage liver disease, liver transplant may be considered. This can correct liver-based functions like clotting and bile production, but it does not cure the underlying glycosylation defect in other organs. Strict selection, extensive evaluation and life-long immunosuppression are required, making this procedure rare and complex in CDG.

5. Epilepsy surgery (rare)
In a minority of patients with focal, drug-resistant epilepsy and a clear removable lesion, epilepsy surgery may be discussed. In COG5-CDG, this scenario is uncommon, but when appropriate, removing a seizure focus can reduce seizure burden and medication load. Pre-surgical evaluation includes advanced imaging and EEG mapping, and risks include neurological deficits and anaesthetic complications.

---

Preventions

1. Genetic counselling before future pregnancies – helps parents understand recurrence risk and options like carrier testing, prenatal diagnosis or preimplantation genetic testing, reducing unexpected recurrence of COG5-CDG in future children.

2. Early diagnosis and enrolment in specialised care – recognising developmental delays, hypotonia and feeding problems early and referring to a metabolic centre allows prompt supportive management and better long-term outcomes.

3. Routine vaccination according to schedule – protects against preventable infections that could be more severe in medically fragile children with CDG, including influenza and pneumococcal disease.

4. Strict infection-prevention practices – handwashing, avoiding sick contacts, prompt treatment of minor infections and good oral hygiene reduce hospitalisations and complications such as pneumonia or sepsis.

5. Monitoring and protecting liver health – regular liver tests, avoidance of unnecessary hepatotoxic drugs and careful dosing of necessary medicines lower additional liver damage risk in a child with COG5-CDG.

6. Regular cardiac and neurological follow-up – routine ECG, echocardiogram and neurological assessments help detect treatable complications early, such as cardiomyopathy, arrhythmias or worsening epilepsy.

7. Bone health surveillance and support – ensuring vitamin D sufficiency, weight-bearing activity when possible and early osteopenia treatment helps prevent fractures and spinal deformity.

8. Safe home and school environment – removing trip hazards, using safety gates and adaptive equipment, and training staff on seizure first-aid prevent injuries during falls or seizures.

9. Regular growth and nutrition checks – early action for faltering growth, swallowing problems or micronutrient deficiencies prevents severe malnutrition and its complications.

10. Psychosocial support to prevent caregiver burnout – counselling, respite and support groups help families stay resilient, which indirectly improves the child’s long-term care and stability.

---

When to see doctors urgently or more often

Families of someone with COG5-CDG should contact a doctor or emergency service immediately if seizures last longer than five minutes or occur back-to-back without full recovery, if breathing becomes fast or difficult, if there is blue discolouration of lips or face, or if the child is unusually sleepy, unresponsive or very irritable. Sudden vomiting with dehydration signs (no urine, dry mouth, sunken eyes), new jaundice, severe abdominal pain, black or bloody stools, or any unusual bleeding or bruising also require urgent assessment. Regular non-urgent visits are needed for growth checks, developmental assessments, liver and heart monitoring, medication review and vaccination updates, ideally in a specialist metabolic or CDG clinic that knows the child’s history.

---

Things to eat and things to avoid

Helpful to eat (as tolerated and guided by a dietitian)

1. Energy-dense foods such as nut butters, avocados and full-fat yoghurts (if safe) to support growth in children with high energy needs and poor appetite.

2. Balanced protein sources like eggs, dairy, beans, lentils, poultry or fish to maintain muscles and immune function.

3. Fruits and vegetables for vitamins, minerals and fibre, choosing textures (pureed, soft) that are safe for swallowing.

4. Whole-grain options (if tolerated) for steady energy and bowel regularity, such as oats, rice or soft whole-grain bread.

5. Fortified formulas or medical nutrition products when oral intake is low, providing controlled calories, protein and micronutrients through bottle, cup or feeding tube.

6. Adequate fluids such as water, oral rehydration solutions and prescribed feeds, adjusted for swallowing safety and risk of aspiration.

7. Healthy fats (olive oil, canola oil, MCT oil if recommended) to increase calories without increasing meal volume too much.

8. Foods rich in calcium and vitamin D (dairy, fortified milks, fish with bones) to support bone strength, if compatible with liver and kidney status.

9. Iron-rich foods like meat, fortified cereals and beans, especially when anaemia is present, combined with vitamin C sources to aid absorption.

10. Small, frequent meals or feeds rather than large meals, to reduce reflux and vomiting and improve tolerance in children with low stamina.

Better to avoid or limit (based on individual medical advice)

1. Very hard, dry or crumbly foods (nuts, raw carrots, chips) that increase choking risk in children with poor chewing and swallowing.

2. Very fatty, greasy meals that may worsen reflux or be poorly tolerated when there is liver disease or malabsorption.

3. High-sugar drinks and sweets which give calories without nutrients and can worsen dental problems and blood sugar swings.

4. Caffeinated drinks and energy drinks in older children and adults, as they may disturb sleep, worsen reflux and interact with some medicines.

5. Herbal or over-the-counter supplements without medical review, because some can stress the liver or interact with antiepileptic and other drugs.

6. Excessive salt intake in patients with heart or liver problems, which can worsen swelling and fluid retention.

7. Raw or undercooked meats, eggs or unpasteurised products that increase infection risk in a medically fragile child.

8. Alcohol in adolescents or adults with COG5-CDG, as it can directly damage the liver and worsen neurological symptoms.

9. Very high-protein fad diets without specialist supervision, which may overburden liver and kidneys in a multisystem metabolic disease.

10. Crash diets or “detox” regimens that cause rapid weight loss, dehydration or electrolyte imbalance, which can be dangerous in individuals with seizures and organ involvement.

---

Frequently asked questions (FAQs)

1. Is COG5-CDG curable?
No. At present there is no cure or disease-specific drug for COG5-CDG. Treatment focuses on managing symptoms, supporting growth and development, and preventing complications through multidisciplinary care and early intervention. Research into targeted therapies, including gene-based approaches, is ongoing but still experimental.

2. How is COG5-CDG diagnosed?
Diagnosis usually involves clinical evaluation, blood tests showing abnormal glycosylation patterns (such as transferrin analysis), genetic testing confirming pathogenic COG5 variants, and sometimes additional organ-function tests. Given its rarity and variable features, diagnosis often occurs in specialised metabolic or genetics centres with experience in CDG.

3. What are the main symptoms families should watch for?
Core symptoms include low muscle tone, delayed motor and speech milestones, poor growth, feeding difficulties, seizures, coordination problems, distinctive facial features, and possible vision or hearing issues. Some patients also develop liver disease, heart problems, or clotting abnormalities, so regular monitoring is essential.

4. What is the life expectancy in COG5-CDG?
Because COG5-CDG is extremely rare and only a small number of patients have been described, long-term survival data are limited. Prognosis varies depending on severity of neurological and organ involvement, seizure control, infections and access to specialised care. Ongoing follow-up with experts helps anticipate and treat complications early.

5. Can children with COG5-CDG attend school?
Many children can attend school with appropriate support, such as special education services, individual education plans, classroom aides and assistive communication devices. The focus is on participation and skills development at the child’s pace, not on comparing them strictly with age-matched peers.

6. Does diet alone treat COG5-CDG?
No. Diet cannot correct the genetic glycosylation defect. However, tailored nutrition and feeding strategies are essential to prevent malnutrition, support growth, and improve general health, and they work together with therapies, medications and other supports.

7. Will all siblings have COG5-CDG?
In autosomal recessive conditions, each pregnancy has a 25% chance of being affected, a 50% chance of being an unaffected carrier and a 25% chance of being unaffected and not a carrier, assuming both parents are carriers. Genetic counselling and testing help clarify risks for individual families.

8. Are vaccines safe for children with COG5-CDG?
In general, standard vaccinations are recommended and important to protect against serious infections. In very special situations (for example, profound immunodeficiency or high-dose immunosuppression), some live vaccines might be delayed or avoided, so the schedule should always be planned with the child’s specialists.

9. Can physical therapy make the disease worse?
When properly tailored, physiotherapy is helpful and does not worsen the underlying disease. Over-aggressive or painful exercises should be avoided, but regular, gentle, goal-directed therapy can improve comfort, posture, strength and functional abilities, even if some limitations remain.

10. Why are so many different doctors involved?
COG5-CDG affects many body systems, so several specialists are needed: neurology for seizures, hepatology for liver disease, cardiology for heart issues, ophthalmology and audiology for vision and hearing, endocrinology for hormones, and rehabilitation specialists for therapy. A coordinated team approach avoids gaps in care.

11. Are experimental treatments available?
Some centres may offer enrolment in research studies on CDG, including trials of supplements, novel drugs or potential gene-based approaches. Participation is voluntary and depends on eligibility, travel and risk-benefit discussions. Families should discuss clinical trials with trusted metabolic specialists and carefully review all information before deciding.

12. How can families find expert centres?
National or regional rare-disease networks, CDG patient organisations and genetics societies often list specialised clinics that manage CDG. Metabolic specialists can also refer families to centres with research programs or multidisciplinary CDG teams. Online resources from recognised rare-disease organisations are a good starting point.

13. Does COG5-CDG get worse over time?
The course is variable. Some children show relatively stable but significant developmental disability; others may develop progressive complications, such as worsening liver disease or vision problems. Regular assessments allow the care team to adjust support as needs change and to address new issues early.

14. What support is available for emotional stress?
Psychologists, social workers, palliative care teams and family support groups can help parents and siblings cope with stress, grief and uncertainty. Sharing experiences with other families affected by CDG often reduces isolation and provides practical tips for daily life and long-term planning.

15. What is the most important message for caregivers?
You did not cause COG5-CDG; it results from genetic changes that neither parent can control. Early, continuous multidisciplinary care, good nutrition, seizure and infection control, and emotional support can significantly improve quality of life for the child and family, even though the condition is rare and currently not curable.

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical  history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: February 03, 2025.